Difference between revisions of "Alvocidib (Flavopiridol)"
Jump to navigation
Jump to search
(Created page with "=Mechanism of action= Flavonoid alkaloid CDK9 kinase inhibitor =History of changes in FDA indication= *4/13/2007: Granted orphan status for treatment of [[Chronic lymphocyti...") |
m |
||
| Line 1: | Line 1: | ||
| − | =Mechanism of action= | + | ==Mechanism of action== |
Flavonoid alkaloid CDK9 kinase inhibitor | Flavonoid alkaloid CDK9 kinase inhibitor | ||
| − | =History of changes in FDA indication= | + | ==Diseases for which it is used== |
| + | *[[Acute myeloid leukemia]] | ||
| + | *[[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)]] | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
*4/13/2007: Granted orphan status for treatment of [[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) | B-cell chronic lymphocytic leukemia (B-CLL)]] or prolymphocytic leukemia arising from CLL. | *4/13/2007: Granted orphan status for treatment of [[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) | B-cell chronic lymphocytic leukemia (B-CLL)]] or prolymphocytic leukemia arising from CLL. | ||
*4/23/2014: Granted orphan designation for the treatment of patients with [[Acute myeloid leukemia | acute myeloid leukemia (AML)]] | *4/23/2014: Granted orphan designation for the treatment of patients with [[Acute myeloid leukemia | acute myeloid leukemia (AML)]] | ||
| + | [[Category:Drug index]] | ||
| + | [[Category:Chemotherapy]] | ||
[[Category:Orphan drug]] | [[Category:Orphan drug]] | ||
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] | ||
| Line 12: | Line 18: | ||
[[Category:Acute myeloid leukemia medications]] | [[Category:Acute myeloid leukemia medications]] | ||
[[Category:Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications]] | [[Category:Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 2007]] | ||
Revision as of 13:55, 1 November 2014
Mechanism of action
Flavonoid alkaloid CDK9 kinase inhibitor
Diseases for which it is used
History of changes in FDA indication
- 4/13/2007: Granted orphan status for treatment of B-cell chronic lymphocytic leukemia (B-CLL) or prolymphocytic leukemia arising from CLL.
- 4/23/2014: Granted orphan designation for the treatment of patients with acute myeloid leukemia (AML)